Arcturus Therapeutics: Strategic Shift Beyond mRNA Vaccines Earns Buy Rating

Whitney Ijem from Canaccord Genuity maintains a Buy rating on Arcturus Therapeutics with a price target of $66.00. Despite the winding down of mRNA vaccine development, the company's contracts, such as the H5N1 program, will continue. The upcoming data update in cystic fibrosis and self-amplifying RNA technology are also significant value drivers. These factors support the positive outlook and potential for future growth and innovation.

Whitney Ijem from Canaccord Genuity has maintained a Buy rating on Arcturus Therapeutics with a price target of $66.00 [1]. This rating is driven by several strategic factors that position the company for future growth and innovation.

Despite the recent announcement from the U.S. Department of Health and Human Services (HHS) about winding down mRNA vaccine development under the Biomedical Advanced Research and Development Authority (BARDA) program, Arcturus Therapeutics' ongoing contracts, such as the H5N1 program, are set to continue. This strategic decision indicates a focus on preserving prior investments and maintaining a broader scope for mRNA technology applications beyond first-generation vaccines.

Additionally, Ijem emphasizes that Arcturus' potential should not be dismissed due to the broader sentiment around mRNA vaccines. Instead, attention is directed towards the company's upcoming data update in cystic fibrosis, which is anticipated to be a significant value driver. Furthermore, Arcturus' self-amplifying RNA technology, which has shown promising results compared to existing solutions, further supports the positive outlook.

These factors collectively underpin the Buy rating, highlighting the potential for future growth and innovation. Despite the shift in focus from mRNA vaccines, Arcturus Therapeutics remains well-positioned to capitalize on new opportunities in the biotechnology sector.

References:
[1] https://www.tipranks.com/news/ratings/arcturus-therapeutics-strategic-focus-beyond-mrna-vaccines-drives-buy-rating-ratings
[2] https://www.nasdaq.com/press-release/geovax-comments-hhs-mrna-vaccine-rollback-urges-full-embrace-mva-based-multi-antigen